At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
BIA 9-1067 +1 moredrug
Likely dose
BIA 9-1067 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating BIA 9-1067 and Repaglinide for Parkinson Disease. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesPortugal
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
Primary CompletionJul 2009
Study CompletionJan 2011
First PostedFeb 2012
TodayJul 2026
First PostedFeb 22, 2012
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2009
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.4 years ago
Interventions
BIA 9-1067drug
25 mg BIA 9-1067 (single-dose)
Repaglinidedrug
0.5 mg repaglinide (single-dose)